Rebounds from Iran Shock...Lunit·Rznomics·Hyundai ADM Rally[K-Bio Pulse]

[Han Kwangbeom, Edaily Reporter] On the 5th the pharmaceutical and biotech sectors successfully staged a dramatic rebound shaking off the previous day‘s disastrous sell off.

As market sentiment quickly shifted from undifferentiated panic selling to “selective focus” prioritizing technical substance and global scalability Lunit, Rznomics and Hyundai ADM emerged as leaders of the recovery.

According to MP DOCTOR (formerly Marketpoint), Lunit (328130), a leader in homegrown medical artificial intelligence (AI), demonstrated strong resilience, closing at 36,100 won, up 8.73%. Analysts attribute this surge to the company’s decisive move toward global market expansion. The release of PharmEdaily‘s premium report, “Lunit Joins Harrison.ai Platform... Green Light for Expansion into U.S. and Overseas Markets,” also appeared to bolster investor confidence.

Lunit stock trend on Mar 5.(Image=MP Doctor)

Lunit Achieves Tangible Integration with Harrison ai Accelerating Entry into Global Healthcare Ecosystems

Lunit has entered into a partnership and joint sales agreement with Harrison.ai, a global healthcare AI firm that possesses a Large Multimodal Model (LMM) specialized in radiology a world first.

This collaboration goes beyond a mere Memorandum of Understanding (MOU) it involves the direct integration of Lunit’s core solutions “Lunit INSIGHT MMG” and “Lunit INSIGHT DBT” into Harrison.ai‘s open platform.

As Harrison.ai is a unicorn company providing its platform to over 1,000 medical institutions across more than 40 countries, including Australia, this partnership provides Lunit with a robust foundation for entering major global medical markets.

Harrison.ai’s open platform is an open ecosystem designed to solve the complexities of AI integration and “vendor lock in” issues faced by hospitals. Lunit‘s high precision cancer diagnostic technology is expected to create significant synergy with Harrison ai’s radiology specific foundation model “Harrison.rad.1.”

This model has demonstrated diagnostic performance approximately twice as high as radiologists who passed the specialist exams acting as a digital assistant that automatically generates draft reports for physicians based on Lunit‘s AI analysis.

Industry insiders expect this strategy to have an impact comparable to Lunit’s previous software integration with Roche Diagnostics. In particula, it is seen as a powerful catalyst for penetrating the conservative U.S. market‘s supply chain and government procurement sectors.

As CEO Brandon Suh stated this partnership provides an excellent foundation for introducing Lunit’s solutions to customers in key global markets strengthening the long term upward trend by increasing the likelihood of being adopted as a “standard screening tool” in U.S. hospitals.

Rznomics stock trend on Mar 5.(Image=MP Doctor)

Rznomics RNA Platform Value Re evaluated Amid Licensing Out (L/O) Expectations

On this day Rznomics closed at the daily upper limit of 151,100 won, soaring 29.92%. This powerful surge effectively neutralized the previous day‘s crash. The rally is backed by Rznomics’ proprietary “Trans-splicing Ribozyme” platform technology.

This next generation gene editing method precisely corrects or replaces mutant RNA that causes diseases. Expectations for a multi billion dollar licensing out (L/O) deal with global Big Pharma have spread throughout the industry, drawing in massive buying interest.

Rznomics is reportedly attracting investor attention due to rumors of ongoing negotiations with major overseas pharmaceutical firms. In particular, the efficacy data obtained from global Phase 1/2a clinical trials for its lead pipeline RZ-001 (a treatment for liver cancer and genetic diseases) has positioned the company as a credible alternative for investors seeking “tangible technology” amid geopolitical risks.

The high exchange rate environment driven by the surging USD has also acted as a favorable factor for Rznomics. Anticipation of a massive dollar-denominated upfront payment upon a potential deal has elevated Rznomics to a “USD asset beneficiary.”

While the upward momentum is strong after breaking through historical highs analysts suggest that the sustainability of the rally will depend on maintaining the 150,000 won support level and the timing of an official contract announcement.

Hyundai ADM stock trend on Mar 5.(Image=MP Doctor)

Hyundai ADM Hits Upper Limit as Audit Uncertainties Ease Short Covering Inflow

The stock that staged the most dramatic turnaround was Hyundai ADM. After crashing to a lower limit (-29.98%) the previous day due to a delayed audit report and war fears, Hyundai ADM rebounded 29.96% to close at 13,750 won, recovering most of its losses in a single day.

This recovery is interpreted as a result of bargain hunting as concerns over a potential “Disclaimer of Opinion” or delisting eased following the company‘s clarifications.

Specifically, after the company announced that it had completed the submission of explanatory materials for the re audit and was doing its best to secure an “Unqualified” opinion the supply demand balance which had tilted toward selling reversed rapidly. This rebound was further amplified by short covering, as those who had bet on a further decline moved to cover their positions to minimize losses.

While this rebound demonstrates Hyundai ADM’s resilience, it also highlights that the stock price remains highly sensitive to investor sentiment and supply demand dynamics rather than fundamentals alone.

Given the nature of the March audit season volatility may persist until the official “Unqualified” opinion is confirmed through a public disclosure. Analysts point to the recovery of previous highs as a key observation point though a cautious approach is advised as profit taking pressure may build following the sharp rise.

Ultimately, the rebound of Lunit, Rznomics, and Hyundai ADM is seen as a result of their unique technical substance and resilience offsetting the uncertainties of geopolitical risks. An industry official noted “The market seems to evaluate that these three companies have presented tangible results global platform integration (Lunit), expectations for a billion dollar deal (Rznomics), and a recovery of trust following company clarifications (Hyundai ADM).”